The first generation of kinase inhibitors, such as breakpoint cluster region-Abelson murine leukemia fusions (BCR-ABL), epidermal growth factor receptor mutations (EGFR), and anaplastic lymphoma kinase rearrangements (ALK), confirmed that they have great therapeutic potential in chronic myeloid leukemia and kinase-driven non-small cell lung cancer (NSCLC) [1,2,3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.